Join the club for FREE to access the whole archive and other member benefits.


Company focused on the research and development of mitochondria based therapeutics.

Our company is a first mover and leader in exploring the mitochondrial genome for therapeutically relevant peptides that have the potential to be developed into transformative and commercially successful drugs. These peptides have been conserved by evolutionary biology due to their important roles in sensing and regulating critical biological functions, far beyond the energy production most frequently associated with mitochondria. Our team has discovered more than 100 mitochondrial derived peptides (MDPs) and generated over 1,000 analogs.

Visit website:

 Login to view link, or join the club to get full access to all resources and other benefits.

People at CohBar

Company Representative

Chief Executive Officer & Director, CohBar

CohBar News

CohBar's lead candidate may initiate clinical trials in 2022

Longevity Technology - 16-Mar-2021

Mitochondrial-based therapy enters IND to tackle IPF and other fibrotic diseases


From cryonic baths to ozone saunas, to the search of magic pill

Wired - 10-Sep-2019

In 2018 consumers spent $43 billion on anti-ageing products according to Orbis analysis